Use of High Resolution Colonic Manometry in Studying Motility

Phase 1

Withdrawn

• Conditions: Gastrointestinal Dysfunction
• Interventions: Other: Saline (Placebo); Drug: Neostigmine; Device: High Resolution Colonic Manometry; Drug: Glycopyrrolate

• Registration Number: NCT02574611
• Lead Sponsor: James J. Peters Veterans Affairs Medical Center

Brief Summary

An injury to the spinal cord (SCI) results in numerous medical complications, including gastrointestinal (GI) function. Individuals with SCI may experience severe constipation (prolonged stool retention), incontinence (accidents), and overall difficulty in bowel evacuation. While various treatments and medications have been established to address this complication, there is little knowledge relating to the overall colonic motility. However, new technology such as High Resolution Colonic Manometry allows physicians to visualize high pressure contractions inside the colon, leading to a greater understanding of typical motility, a more accurate diagnosis, and an effective treatment. In this study, the investigators propose to use this technology to understand the effects of SCI on colonic motility by comparing to normal colonic function observed in able-bodied (AB) individuals. In addition, the investigators plan to study the effects of pharmacological treatments, such as neostigmine, on promoting peristaltic contractions in the colon as it is delivered across the skin.

Detailed Description

The investigators data suggests that the fundamental consequence of SCI is a slowing of intestinal peristaltic activity, most likely as a result of down regulation of parasympathetic neural pathways. Furthermore, the investigators have effectively shown that measures involved in increase parasympathetic stimulation results in efficient bowel evacuation and improved bowel care. Such measures include the administration of neostigmine (NEO), which increases peristaltic contractions in the colon, resulting in predictable bowel evacuations. Given the cardiopulmonary side-effects of NEO, an ant-cholinergic known as Glycopyrrolate (GLY) is usually co-administered with NEO to reverse these side effects. However, the investigators knowledge regarding the effects of SCI on colonic motility is still primitive, mainly due to pervious technological disadvantages. New High Resolution Colonic Manometry systems (Medical Measurement Systems Dover, NH) simultaneously capture high amplitude pressure contractions (HAPCs) across the ascending, transverse, descending, and recto-sigmoid colon. Such capabilities allow for a much clearer display of pressure events compared to previous line tracing manometric systems and the direction of contractions are much easier to discern as well. To date, this technology has been an effective tool in diagnosing bowel disorders and complications, such as constipation in able-bodied individuals (AB). However, such studies have not been conducted in a SCI population. This technology also has the potential to capture the effects of NEO+GLY on improving colonic function.

Study Timeline

• Study First Submitted: 2015-10-06
• Study First Submitted QC: 2015-10-09
• Study Start: 2015-10-13
• Study First Posted: 2015-10-14
• Primary Completion: 2017-12-25
• Study Completion: 2018-12-25
• Status Verified: 2021-09
• Last Update Submitted: 2021-09-22
• Last Update Posted: 2021-09-28

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Chronic SCI >1year
• Able-Bodied (non SCI)
• Undergoing Elective Colonoscopy
• Age 18-75 years.

Exclusion Criteria

• Previous adverse reaction or hypersensitivity to electrical stimulation
• Known sensitivity to neostigmine or glycopyrrolate
• Persons with SCI who do not require additional bowel care or have "normal bowel function"
• Known hypersensitivity to neostigmine or glycopyrrolate
• History of mechanical obstruction of the intestine or urinary tract
• History of Myocardial infarction
• Uncontrollable Hypertension Defined by a blood pressure reading of 160/100 mmHg or higher
• Organ damage (heart & kidney) and/or transient ischemic attack-cerebral vascular accident as a result of hypertension
• Known past history of coronary artery disease or bradyarrythmia
• Active respiratory disease
• Known history of asthma during lifetime or recent (within 3 months) respiratory infections
• Adrenal insufficiency
• Diagnosed coagulopathy
• Any renal disease or dysfunction
• Potential for pregnancy
• Lactating/nursing females
• Slow-heart beat (HR<45 bpm)
• Lack of mental capacity to give consent
• Use of any antibiotic in the past 7 days
• Use of medications known to affect the respiratory system
• Use of medications known to alter airway caliber
• Concurrent participation in other clinical trials (within 30 days)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
SCI placebo group	High Resolution Colonic Manometry	Individuals with SCI will undergo a second day of observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of normal saline solution (placebo).
SCI placebo group	Saline (Placebo)	Individuals with SCI will undergo a second day of observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of normal saline solution (placebo).
SCI observational	High Resolution Colonic Manometry	Individuals with SCI will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during a "typical" day (eating, sleeping, mobility, etc.).
Able-bodied observational	High Resolution Colonic Manometry	Able-bodied individuals (non SCI) will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during a "typical" day (eating, sleeping, mobility, etc.).
SCI drug group	Neostigmine	Individuals with SCI will undergo a second day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of neostigmine and glycopyrrolate.
SCI drug group	High Resolution Colonic Manometry	Individuals with SCI will undergo a second day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of neostigmine and glycopyrrolate.
SCI drug group	Glycopyrrolate	Individuals with SCI will undergo a second day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of neostigmine and glycopyrrolate.

Primary Outcome Measures

Name	Time	Method
High Amplitude Contractions	1-2days	Monitor changes in High Amplitude Contractions inside the colon during a typical day for SCI and AB patients. The manometry system will record these changes and allow the investigators to visualize changes during various activities (eating, resting, supine, seated, walking, etc.) The investigators will also measure changes in contractions during administration of prokinetic agents to promote bowel evacuations

Trial Locations

Locations (1)

James J. Peters VA Medical Center; 🇺🇸 Bronx, New York, United States